会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD OF MODULATING NEOVASCULARIZATION
    • 调节新生血管的方法
    • WO2009126725A1
    • 2009-10-15
    • PCT/US2009/039932
    • 2009-04-08
    • THE REGENTS OF THE UNIVERSITY OF MICHIGANWEISS, StephenROWE, Robert, G.
    • WEISS, StephenROWE, Robert, G.
    • C07K16/18C07K14/315C07K14/78A61K39/395A61K38/39A61P43/00A61P9/00
    • C07K16/22A61K38/164A61K38/39A61K39/00A61K2039/505C07K14/78C07K16/18G01N33/5026
    • The disclosure provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The disclosure also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization.
    • 本公开提供了抑制受试者中新生血管形成的方法。 该方法包括以有效抑制新血管形成的量向受试者施用干扰纤连蛋白(Fn)基质组合物的药剂。 本公开还提供了鉴定抑制新血管形成的药剂的方法。 该方法包括在存在和不存在药剂的情况下,通过在三维培养凝胶中培养的受激内皮细胞检测纤连蛋白(Fn)基质装配体。 在不存在药物的情况下,与Fn基质组装相比,在药剂存在下Fn基质组装的减少指示抑制新生血管形成的药剂。 或者,识别抑制新血管形成的药剂的方法包括检测在存在和不存在药剂的情况下在三维培养凝胶中培养的受刺激的内皮细胞中的核结构的变化。 核建筑组织的减少确定了抑制新血管形成的药物。